W
WAVEMAN · COMPANY
XERS · Xeris Biopharma Holdings, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

XERS

Xeris Biopharma Holdings, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001867096
FORM 144 · 5☆ WATCH
INSIDER NET · 180D
-$2.6M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
144
13F, latest reported quarter
REVENUE GROWTH
+43.7%
XBRL, annual
NET MARGIN
0.2%
CONVERSIONS · 180D
2
codes C/M, not in net · $200.0K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$2.6M over 180 days
-$1.8M over 90 days
below 71% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
144 funds added or opened last quarter
more than 77% of Pharma & Biotech
REVENUE
+43.7% year over year
more than 77% of Pharma & Biotech
MARGIN
0.2% net margin
more than 66% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$2.6M across 8 people in 180 days.
144 funds added or opened positions in the latest 13F quarter, of 245 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +7.7%
+7.7%12M
-33%-14%+6%+25%2025-092025-102025-122026-032026-052026-072026-09 2025-12-19 · JOHNSON JOHN sold $977.6K2026-07-01 · McCulloch Kevin sold $722.5K2026-07-07 · Pieper Steven sold $235.3K2026-01-05 · Shannon John Patrick Jr sold $176.3K2025-11-13 · Shannon John Patrick Jr sold $173.4K2026-07-06 · Pieper Steven sold $147.9K2026-09-01 · Hecht Beth sold $141.4K2026-07-01 · Hecht Beth sold $133.9K2026-08-03 · Hecht Beth sold $133.6K2026-09-01 · McCulloch Kevin sold $127.3K2026-02-02 · Hecht Beth sold $124.2K2026-01-02 · Hecht Beth sold $123.8K2025-11-11 · Hecht Beth sold $123.3K2026-06-04 · HALKUFF DAWN sold $121.8K2026-08-03 · McCulloch Kevin sold $120.2K2026-01-08 · McCulloch Kevin sold $120.0K2025-09-11 · PERSKY MARLA sold $119.7K2025-12-01 · Hecht Beth sold $116.8K2025-12-12 · BORMANN-KENNEDY BARBARA-JEAN ANNE sold $106.3K2026-05-01 · Hecht Beth sold $103.8K2026-03-02 · Hecht Beth sold $103.4K2026-06-01 · Hecht Beth sold $101.0K2026-04-01 · Hecht Beth sold $99.8K2026-06-04 · BORMANN-KENNEDY BARBARA-JEAN ANNE sold $97.4K2026-06-03 · PERSKY MARLA sold $91.5K2026-06-04 · JOHNSON JOHN sold $91.3K2026-03-30 · Brady James Aloysius sold $60.0K2026-09-01 · Pieper Steven sold $42.5K2026-08-12 · Pieper Steven sold $42.5K2026-03-02 · Hecht Beth sold $7062026-08-12 · STEVEN PIEPER filed to sell $167.8K2026-07-07 · STEVEN PIEPER filed to sell $231.0K2026-07-06 · STEVEN PIEPER filed to sell $144.1K2026-07-01 · BETH HECHT filed to sell $396.0K2026-07-01 · KEVIN MCCULLOCH filed to sell $950.4K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $2.6M sold by insiders over 180 days, 144 funds added last quarter, $1.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Xeris Biopharma Holdings, Inc. insiders sold a net $2.6M of stock across 54 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
McCulloch Kevin
See Remarks
SELL
2026-09-01
15,000.0
$127.3K
Hecht Beth
See Remarks
SELL
2026-09-01
16,666.0
$141.4K
Pieper Steven
See Remarks
SELL
2026-09-01
5,000.0
$42.5K
Pieper Steven
See Remarks
SELL
2026-08-12
5,000.0
$42.5K
Hecht Beth
See Remarks
SELL
2026-08-03
16,666.0
$133.6K
54 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 49 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
14,525,539.0 sh
$115.0M
D. E. Shaw & Co., Inc.
7,804,758.0 sh
$61.8M
VANGUARD CAPITAL MANAGEMENT LLC
7,340,229.0 sh
$58.1M
STATE STREET CORP
4,821,566.0 sh
$38.2M
GEODE CAPITAL MANAGEMENT, LLC
4,718,183.0 sh
$37.4M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
STEVEN PIEPER
FILED 2026-08-12
$167.8K
STEVEN PIEPER
FILED 2026-07-07
$231.0K
STEVEN PIEPER
FILED 2026-07-06
$144.1K
BETH HECHT
FILED 2026-07-01
$396.0K
KEVIN MCCULLOCH
FILED 2026-07-01
$950.4K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.7M POSITION · AS OF 2026-03-31
1.8%
PROFUND VP PHARMACEUTICALS
$179.5K POSITION · AS OF 2026-03-31
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$174.7K POSITION · AS OF 2026-04-30
1.4%
F/m Emerald Life Sciences Innovation ETF
$1.3M POSITION · AS OF 2026-02-28
1.3%
1290 Essex Small Cap Growth Fund
$1.1M POSITION · AS OF 2026-04-30
1.0%
Royce Smaller-Companies Growth Fund
$1.5M POSITION · AS OF 2026-03-31
0.8%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Mr. Edic
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$5.0M
$12.0M
$2.0M
+60%
+25%
2023
$2.1M
$3.5M
$1.3M
-52%
-6%
2022
$2.8M
$1.0M
$1.4M
-73%
-10%
2021
$3.8M
$2.3M
$1.7M
-40%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122024-032023-12
REVENUE$291.8M$203.1M—$163.9M
OPERATING INCOME$24.9M$-33.6M—$-44.0M
NET INCOME$554.0K$-54.8M—$-62.3M
EPS (DILUTED)0.00-0.37—-0.45
OPERATING CASH FLOW$28.6M$-37.0M—$-47.0M
CASH$111.0M$71.6M$62.7M$67.4M
LONG-TERM DEBT$220.3M$217.0M$229.7M$190.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →